MCID: FML039
MIFTS: 38

Female Reproductive System Disease

Categories: Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Female Reproductive System Disease

MalaCards integrated aliases for Female Reproductive System Disease:

Name: Female Reproductive System Disease 11 14 16
Female Reproductive System Disorder 71
Genital Diseases, Female 43

Classifications:



External Ids:

Disease Ontology 11 DOID:229
ICD9CM 34 629.9
MeSH 43 D005831
SNOMED-CT 68 38233001
UMLS 71 C0017411 C0236100

Summaries for Female Reproductive System Disease

Disease Ontology: 11 A reproductive system disease that impairs the ability to reproduce and is located in the uterus, vagina, cervix, ovaries or fallopian tubes.

MalaCards based summary: Female Reproductive System Disease, also known as female reproductive system disorder, is related to uterine anomalies and ovarian disease, and has symptoms including menometrorrhagia, mastodynia and breast engorgement. An important gene associated with Female Reproductive System Disease is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways are miRNAs involved in DNA damage response and miRNAs involvement in the immune response in sepsis. The drugs Dydrogesterone and Progesterone have been mentioned in the context of this disorder. Affiliated tissues include cervix, uterus and breast.

Related Diseases for Female Reproductive System Disease

Diseases related to Female Reproductive System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 311)
# Related Disease Score Top Affiliating Genes
1 uterine anomalies 32.8 MIR9-1 MIR518D MIR518A1 MIR34A MIR30A MIR214
2 ovarian disease 32.8 MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
3 endometriosis 32.7 MIR200A MIR199A1 MIR17 MIR145 MIR143 MIR142
4 endometriosis of ovary 32.7 MIR9-1 MIR199A1 MIR145 MIR141 MIR139
5 preterm premature rupture of the membranes 11.2
6 ectopic pregnancy 11.2
7 pelvic inflammatory disease 11.2
8 fallopian tube endometriosis 11.2
9 endosalpingiosis 11.2
10 endometriosis of intestine 11.2
11 endometriosis of pelvic peritoneum 11.2
12 endometriosis in scar of skin 11.2
13 endometriosis of rectovaginal septum and vagina 11.2
14 vaginal disease 11.2
15 hernia of ovary and fallopian tube 11.2
16 prolapse of female genital organ 11.2
17 amenorrhea 11.2
18 masters-allen syndrome 11.2
19 fallopian tube disease 11.2
20 vulvar disease 11.2
21 vulvovaginitis 11.2
22 gynatresia 11.2
23 parovarian cyst 11.2
24 bartholin's gland disease 11.2
25 bartholin's duct cyst 11.2
26 nervous system disease 10.7 MIR9-1 MIR518D MIR518A1 MIR34A MIR30A MIR214
27 reproductive system disease 10.7 MIR9-1 MIR518D MIR518A1 MIR34A MIR30A MIR214
28 bladder disease 10.7 MIR9-1 MIR34A MIR30A MIR214 MIR21 MIR200A
29 gastrointestinal system disease 10.7 MIR9-1 MIR518D MIR518A1 MIR34A MIR30A MIR214
30 gastrointestinal system cancer 10.7 MIR9-1 MIR518D MIR518A1 MIR34A MIR30A MIR214
31 endocrine gland cancer 10.7 MIR9-1 MIR518D MIR518A1 MIR34A MIR30A MIR214
32 respiratory system disease 10.7 MIR9-1 MIR518D MIR518A1 MIR34A MIR30A MIR214
33 hepatocellular carcinoma 10.7 MIR9-1 MIR518D MIR518A1 MIR34A MIR30A MIR214
34 lung cancer 10.7 MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
35 stomach disease 10.7 MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
36 connective tissue disease 10.7 MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
37 large intestine cancer 10.7 MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
38 intestinal disease 10.7 MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
39 thoracic cancer 10.7 MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
40 male reproductive organ cancer 10.7 MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
41 central nervous system cancer 10.7 MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
42 breast disease 10.7 MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
43 immune system disease 10.7 MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
44 endocrine system disease 10.7 MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
45 pancreas disease 10.7 MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
46 cervix disease 10.7 MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
47 ovary epithelial cancer 10.7 MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
48 connective tissue cancer 10.7 MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
49 lymphatic system disease 10.7 MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21
50 bone cancer 10.7 MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21

Graphical network of the top 20 diseases related to Female Reproductive System Disease:



Diseases related to Female Reproductive System Disease

Symptoms & Phenotypes for Female Reproductive System Disease

UMLS symptoms related to Female Reproductive System Disease:


menometrorrhagia; mastodynia; breast engorgement; nipple discharge; leukorrhea; vaginal pruritus; vaginal odor; vaginal discomfort; pruritus vulvae; genital itching; perineal pain female; genitalia external painful; menopausal symptoms; vaginal pain; burning feeling vagina; mastoscirrhus; discomfort of vulva

Drugs & Therapeutics for Female Reproductive System Disease

Drugs for Female Reproductive System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dydrogesterone Approved, Investigational, Withdrawn Phase 4 152-62-5 9051
2
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
3 Hormones Phase 4
4 Hormone Antagonists Phase 4
5 Progestins Phase 4
6
Bevacizumab Approved, Investigational Phase 3 216974-75-3 135329020
7
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
8
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
9 Angiogenesis Inhibitors Phase 3
10 Antineoplastic Agents, Immunological Phase 3
11 Albumin-Bound Paclitaxel Phase 3
12 Antimitotic Agents Phase 3
13 Tubulin Modulators Phase 3
14
Niraparib Approved, Investigational Phase 2 1038915-60-4 24958200
15
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
16
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3 3680
17
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 3003 5743
18
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
19
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
20
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
21
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
22
Olaparib Approved Phase 2 763113-22-0 23725625
23 Pharmaceutical Solutions Phase 2
24 Vaccines Phase 2
25 Immunologic Factors Phase 2
26 Antineoplastic Agents, Hormonal Phase 2
27 Alkylating Agents Phase 2
28 Antineoplastic Agents, Alkylating Phase 2
29 Antiemetics Phase 2
30 glucocorticoids Phase 2
31 Anti-Inflammatory Agents Phase 2
32 Gastrointestinal Agents Phase 2
33 Anti-Bacterial Agents Phase 2
34 Anti-Infective Agents Phase 2
35 Antifungal Agents Phase 2
36 Antibiotics, Antitubercular Phase 2
37 Immunosuppressive Agents Phase 2
38 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
39
Lidocaine Approved, Vet_approved 137-58-6 3676
40
Ritonavir Approved, Investigational 155213-67-5 392622
41
Racivir Approved, Investigational 143491-57-0, 143491-54-7 60877
42
Heparin, bovine Approved, Investigational, Withdrawn 9005-49-6 22833565 9812414 772
43
Nadroparin Approved, Investigational
44
Tenofovir Experimental, Investigational 147127-20-6, 202138-50-9 464205 6398764
45 Insulin, Globin Zinc
46
Insulin
47 Anti-Arrhythmia Agents
48 Sodium Channel Blockers
49 Anesthetics, Local
50 Anesthetics

Interventional clinical trials:

(show all 23)
# Name Status NCT ID Phase Drugs
1 Oral Dydrogesterone Versus Micronized Vaginal Progesterone for Luteal Phase Support in In Vitro Fertilisation (IVF)/ IntraCytoplasmic Sperm Injection (ICSI): Pharmacokinetics and the Impact on the Endometrium, the Microbiota of the Genital Tract and the Peripheral Immunology. Double Blind Crossover Study. Completed NCT03677336 Phase 4 Dydrogesterone Oral Tablet;Micronized progesterone;Placebo Dydrogesterone oral tablet;Placebo Micronized progesterone
2 Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy : A Prospective, Randomized, Controlled Study Unknown status NCT02097446 Phase 3
3 A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer Completed NCT01462890 Phase 3 Paclitaxel;Carboplatin
4 A Single-arm, Prospective, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer Unknown status NCT04556071 Phase 2 Niraparib;Bevacizumab
5 Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II. Completed NCT03562897 Phase 2
6 A Placebo-Controlled, Dose-Ranging Study of Quadrivalent HPV Virus-Like Particle (VLP) Vaccine in 16- to 23-Year-Old Women Completed NCT00365716 Phase 2
7 Phase 2 Study of Efficacy and Safety of Trabectedin in Subjects With Advanced Ovarian Cancer Completed NCT00050414 Phase 2 Trabectedin;Dexamethasone
8 Activity, Tolerability, Safety of Temsirolimus in Women With Ovarian Cancer Who Progressed During Previous Platinum Chemotherapy or Within 6 Months After Therapy or Advanced Endometrial Carcinoma Completed NCT01460979 Phase 2 Temsirolimus
9 A Prospective, Single-arm, Single-center, Exploratory Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Recruiting NCT04566952 Phase 2 Anlotinib;Olaparib
10 A Prospective, Single-arm, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer Not yet recruiting NCT04807166 Phase 2 Drug: Anlotinib;Drug: Carboplatin/Paclitaxel
11 Use of the LANDA Embryo Freezing Technique to Validate Frozen Embryo Transfer Success Rates Unknown status NCT01271400
12 Effect of Metabolic Variations Upon the Activity of the Neuroendocrine Reproductive Axis in Normal Female Volunteers Completed NCT02233283
13 Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects Completed NCT02747641
14 A Long Term Follow up of Perigee Anterior Meshes Performed for Recurrent Prolapse Completed NCT02642835
15 The Effect of Buffered Lidocaine Versus Nonbuffered Lidocaine on Pain Scores During Infiltration for Vulvar Biopsies Completed NCT02698527 Non-Buffered Lidocaine;Buffered Lidocaine
16 Transrectal Ultrasound and 3D Transabdominal Ultrasound in Comparison to Vaginoscopy in Virgins With Suspected Genital Tract Lesions Completed NCT04858919
17 Effect of Total Salpingectomy During Conservative Hysterectomy for Benign Disease on Ovarian Function: Non Inferiority Randomized Controlled Trial Completed NCT01628432
18 Influence of Raltegravir-Containing Antiretroviral Therapy (ART) on Immune Reconstitution and Activation in the Female Genital Tract Completed NCT01456962
19 A Randomized Study Comparing Four Different Postoperative Follow-up Strategies for Improved Postoperative Recovery After Benign Hysterectomy Completed NCT01526668
20 Studio Pilota Farmacocinetico-clinico Sulla Somministrazione di Eparina a Basso Peso Molecolare e Dosaggio Sierico di HGF Nelle Pazienti Operate Affette da Patologie Ginecologiche Completed NCT01523652
21 Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer Recruiting NCT04678414
22 Can SMS-reminders Result in Increased Participation in Cervical Screening? Recruiting NCT04061967
23 Study of Ovarian Function and Gynecological Profile of Patients Carrying a Pathogenic Variant of the HNF1B Gene (GYN-HNF1) Not yet recruiting NCT04746053

Search NIH Clinical Center for Female Reproductive System Disease

Cochrane evidence based reviews: genital diseases, female

Genetic Tests for Female Reproductive System Disease

Anatomical Context for Female Reproductive System Disease

Organs/tissues related to Female Reproductive System Disease:

MalaCards : Cervix, Uterus, Breast

Publications for Female Reproductive System Disease

Articles related to Female Reproductive System Disease:

# Title Authors PMID Year
1
Integrated Analysis Identifies Four Genes as Novel Diagnostic Biomarkers Which Correlate with Immune Infiltration in Preeclampsia. 62
35528613 2022
2
Evidence-based core information for health communication of tobacco control: The effect of smoking on risks of female disease. 62
36330111 2022
3
[Analysis on reproductive health status and influencing factors of female workers of pharmaceutical industry in Gansu province]. 62
22356709 2011

Variations for Female Reproductive System Disease

Expression for Female Reproductive System Disease

Search GEO for disease gene expression data for Female Reproductive System Disease.

Pathways for Female Reproductive System Disease

GO Terms for Female Reproductive System Disease

Cellular components related to Female Reproductive System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.77 MIR9-1 MIR30A MIR214 MIR21 MIR200A MIR199A1
2 extracellular vesicle GO:1903561 9.5 MIR34A MIR30A MIR214 MIR21 MIR193A MIR17

Biological processes related to Female Reproductive System Disease according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 10 MIR9-1 MIR34A MIR214 MIR21 MIR199A1 MIR17
2 cellular response to hypoxia GO:0071456 9.91 MIR34A MIR214 MIR17 MIR126
3 positive regulation of angiogenesis GO:0045766 9.91 MIR30A MIR21 MIR199A1 MIR143 MIR126
4 positive regulation of protein kinase B signaling GO:0051897 9.9 MIR21 MIR199A1 MIR143 MIR126
5 miRNA-mediated gene silencing GO:0035195 9.84 MIR126 MIR139 MIR141 MIR142 MIR143 MIR145
6 negative regulation of inflammatory response GO:0050728 9.83 MIR126 MIR141 MIR142 MIR145 MIR199A1
7 negative regulation of osteoblast differentiation GO:0045668 9.81 MIR9-1 MIR214 MIR17
8 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.81 MIR214 MIR21 MIR17
9 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.76 MIR199A1 MIR196A1 MIR193A
10 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.75 MIR145 MIR199A1 MIR21
11 negative regulation of cell migration GO:0030336 9.73 MIR9-1 MIR34A MIR214 MIR21 MIR145 MIR126
12 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.71 MIR34A MIR214 MIR21
13 positive regulation of blood vessel endothelial cell migration GO:0043536 9.71 MIR30A MIR200A MIR143 MIR126
14 negative regulation of vascular endothelial cell proliferation GO:1905563 9.67 MIR34A MIR193A MIR126
15 negative regulation of vascular endothelial growth factor production GO:1904046 9.65 MIR34A MIR199A1 MIR17
16 angiotensin-activated signaling pathway GO:0038166 9.64 MIR145 MIR143
17 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.63 MIR21 MIR17
18 aorta smooth muscle tissue morphogenesis GO:0060414 9.62 MIR145 MIR143
19 negative regulation of lamellipodium assembly GO:0010593 9.62 MIR214 MIR196A1
20 positive regulation of metalloendopeptidase activity GO:1904685 9.61 MIR21 MIR17
21 negative regulation of BMP secretion GO:2001285 9.59 MIR214 MIR17
22 regulation of phenotypic switching GO:1900239 9.57 MIR145 MIR143
23 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.56 MIR17 MIR143
24 positive regulation of cellular response to hypoxia GO:1900039 9.55 MIR21 MIR145
25 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.55 MIR126 MIR145 MIR17 MIR21 MIR9-1
26 positive regulation of connective tissue replacement GO:1905205 9.54 MIR34A MIR214 MIR199A1
27 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.5 MIR214 MIR199A1 MIR17
28 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.46 MIR145 MIR143
29 negative regulation of angiogenesis GO:0016525 9.43 MIR34A MIR214 MIR21 MIR193A MIR145 MIR143

Molecular functions related to Female Reproductive System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.8 MIR9-1 MIR34A MIR30A MIR214 MIR21 MIR199A1
2 mRNA base-pairing translational repressor activity GO:1903231 9.55 MIR9-1 MIR518A1 MIR34A MIR30A MIR214 MIR21

Sources for Female Reproductive System Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....